HK1021974A1 - Pyridyl alkene-and pyridyl alkine-acid amides as cytostatics and immunosuppressives - Google Patents

Pyridyl alkene-and pyridyl alkine-acid amides as cytostatics and immunosuppressives

Info

Publication number
HK1021974A1
HK1021974A1 HK99106092A HK99106092A HK1021974A1 HK 1021974 A1 HK1021974 A1 HK 1021974A1 HK 99106092 A HK99106092 A HK 99106092A HK 99106092 A HK99106092 A HK 99106092A HK 1021974 A1 HK1021974 A1 HK 1021974A1
Authority
HK
Hong Kong
Prior art keywords
pyridyl
acid amides
alkene
alkine
immunosuppressives
Prior art date
Application number
HK99106092A
Other languages
English (en)
Inventor
Elfi Biedermann
Max Hasmann
Roland Loser
Benno Rattel
Friedemann Reiter
Klaus Seibel
Klaus Vogt
Barbara Schein
Original Assignee
Fujisawa Deutschland Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fujisawa Deutschland Gmbh filed Critical Fujisawa Deutschland Gmbh
Publication of HK1021974A1 publication Critical patent/HK1021974A1/xx

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56Amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/553Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
    • C07F9/576Six-membered rings
    • C07F9/59Hydrogenated pyridine rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F9/00Compounds containing elements of Groups 5 or 15 of the Periodic System
    • C07F9/02Phosphorus compounds
    • C07F9/547Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
    • C07F9/6558Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
    • C07F9/65583Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
HK99106092A 1996-06-20 1999-12-23 Pyridyl alkene-and pyridyl alkine-acid amides as cytostatics and immunosuppressives HK1021974A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19624659A DE19624659A1 (de) 1996-06-20 1996-06-20 Neue Pyridylalken- und Pyridylalkinsäureamide
PCT/EP1997/003245 WO1997048696A1 (en) 1996-06-20 1997-06-20 Pyridyl alkene- and pyridyl alkine- acid amides as cytostatics and immunosuppressives

Publications (1)

Publication Number Publication Date
HK1021974A1 true HK1021974A1 (en) 2000-07-21

Family

ID=7797501

Family Applications (1)

Application Number Title Priority Date Filing Date
HK99106092A HK1021974A1 (en) 1996-06-20 1999-12-23 Pyridyl alkene-and pyridyl alkine-acid amides as cytostatics and immunosuppressives

Country Status (20)

Country Link
US (3) US7241745B2 (ja)
EP (1) EP0923570B1 (ja)
JP (1) JP4225572B2 (ja)
CN (2) CN1152032C (ja)
AT (1) ATE224888T1 (ja)
AU (1) AU736206B2 (ja)
BR (1) BR9709823B1 (ja)
CA (1) CA2257448C (ja)
CZ (1) CZ291791B6 (ja)
DE (2) DE19624659A1 (ja)
DK (1) DK0923570T3 (ja)
ES (1) ES2179351T3 (ja)
HK (1) HK1021974A1 (ja)
HU (1) HU225715B1 (ja)
IL (1) IL127352A (ja)
PT (1) PT923570E (ja)
RU (1) RU2200734C2 (ja)
TR (1) TR199802651T2 (ja)
WO (1) WO1997048696A1 (ja)
ZA (1) ZA975437B (ja)

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19756235A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperidinylsubstituierte Pyridylalkan- alken- und -alkincarbonsäureamide
DE19756261A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue arylsubstituierte Pyridylalkan-, alken- und alkincarbonsäureamide
DE19756212A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue, mit einem cyclischen Imid substituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19756236A1 (de) * 1997-12-17 1999-07-01 Klinge Co Chem Pharm Fab Neue piperazinylsubstituierte Pyridylalkan-, alken- und -alkincarbonsäureamide
DE19818044A1 (de) * 1998-04-22 1999-10-28 Klinge Co Chem Pharm Fab Verwendung von Vitamin-PP-Verbindungen
ATE280157T1 (de) * 1998-11-17 2004-11-15 Hoffmann La Roche 4-aroyl-piperidin-ccr-3 rezeptor antagonisten iii
EP1031564A1 (en) * 1999-02-26 2000-08-30 Klinge Pharma GmbH Inhibitors of cellular nicotinamide mononucleotide formation and their use in cancer therapy
US6432432B1 (en) 1999-03-05 2002-08-13 Arch Chemicals, Inc. Chemical method of making a suspension, emulsion or dispersion of pyrithione particles
CO5180550A1 (es) 1999-04-19 2002-07-30 Smithkline Beecham Corp Inhibidores de fab i
CO5370679A1 (es) 1999-06-01 2004-02-27 Smithkline Beecham Corp Inhibidores fab 1
UY26380A1 (es) 1999-10-08 2001-04-30 Smithkline Beecham Corp Inhibidores de fab i
US6730684B1 (en) 1999-10-08 2004-05-04 Affinium Pharmaceuticals, Inc. Fab I inhibitors
US6762201B1 (en) 1999-10-08 2004-07-13 Affinium Pharmaceuticals, Inc. Fab I inhibitors
DK1560584T3 (da) 2001-04-06 2009-05-18 Affinium Pharm Inc Fab I inhibitorer
EP1348434A1 (en) * 2002-03-27 2003-10-01 Fujisawa Deutschland GmbH Use of pyridyl amides as inhibitors of angiogenesis
DK1599468T3 (da) 2003-01-14 2008-02-04 Arena Pharm Inc 1,2,3-trisubstituerede aryl- og heteroarylderivater som modulatorer af metabolisme og forebyggelse og behandling af forstyrrelser forbundet dermed såsom diabetes og hyperglykæmi
CA2571710A1 (en) 2004-06-24 2006-11-02 Nicholas Valiante Small molecule immunopotentiators and assays for their detection
DOP2006000010A (es) 2005-01-10 2006-07-31 Arena Pharm Inc Procedimiento para preparar eteres aromáticos
US20110045065A1 (en) * 2005-07-11 2011-02-24 Ashok Vasantray Vyas Substance having antioxidant, geroprotective and anti-ischemic activity and method for the preparation thereof
WO2007053498A1 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
WO2007053499A2 (en) 2005-11-01 2007-05-10 Millennium Pharmaceuticals, Inc. Compounds useful as antagonists of ccr2
WO2008009122A1 (en) 2006-07-20 2008-01-24 Affinium Pharmaceuticals, Inc. Acrylamide derivatives as fab i inhibitors
WO2008026018A1 (en) 2006-09-01 2008-03-06 Topotarget Switzerland Sa New method for the treatment of inflammatory diseases
EP2125802A4 (en) 2007-02-16 2014-08-20 Debiopharm Int Sa SALTS, PRODRUGS AND POLYMORPHES OF FAB I INHIBITORS
EP2098231A1 (en) 2008-03-05 2009-09-09 Topotarget Switzerland SA Use of NAD formation inhibitors for the treatment of ischemia-reperfusion injury
US9006426B2 (en) 2008-06-24 2015-04-14 Topotarget A/S Squaric acid derivatives as inhibitors of the nicotinamide
MX2011002240A (es) 2008-08-29 2011-04-05 Topotarget As Nuevos derivados de urea y tiourea.
CN102421754B (zh) * 2009-05-12 2013-11-27 北京世桥生物制药有限公司 丙烯酰胺类衍生物及其制备药物的用途
CA2768338A1 (en) 2009-07-17 2011-01-20 Topotarget A/S Method for predicting the utility of administering nicotinic acid or a precursor or prodrug thereof to reduce the severity of side-effects of cancer treatment with nicotinamide phosphoribosyltransferase inhibitors
WO2011121055A1 (en) 2010-03-31 2011-10-06 Topotarget A/S Pyridinyl derivatives comprising a cyanoguanidine or squaric acid moiety
JP6038792B2 (ja) 2010-09-03 2016-12-07 フォーマ ティーエム, エルエルシー. 癌などの疾患の治療のためのnampt阻害剤としての4−{[(ピリジン−3−イル−メチル)アミノカルボニル]アミノ}ベンゼン−スルホン誘導体
RU2617988C2 (ru) 2010-09-03 2017-05-02 ФОРМА ТиЭм, ЭлЭлСИ Новые соединения и композиции для ингибирования nampt
AR082886A1 (es) 2010-09-03 2013-01-16 Forma Therapeutics Inc Compuestos y composiciones farmaceuticas que los contienen
US10894787B2 (en) 2010-09-22 2021-01-19 Arena Pharmaceuticals, Inc. Modulators of the GPR119 receptor and the treatment of disorders related thereto
ES2622881T3 (es) * 2010-09-29 2017-07-07 Intervet International B.V. Compuestos de N-heteroarilo
US9302989B2 (en) 2010-11-15 2016-04-05 Abbvie Inc. NAMPT and rock inhibitors
MX2013005479A (es) 2010-11-15 2013-06-12 Abbvie Inc Inhibidores de nampt.
CN103717574B (zh) 2011-05-04 2017-02-22 福马Tm有限责任公司 用于抑制nampt的新化合物和组合物
WO2012154194A1 (en) * 2011-05-09 2012-11-15 Forma Tm, Llc Piperidine derivatives and compositions for the inhibition of nicotinamide phosphoribosyltransferase (nampt)
EP2736887B1 (en) 2011-07-29 2017-10-18 Karyopharm Therapeutics, Inc. Hydrazide containing nuclear transport modulators and uses thereof
PT3404027T (pt) 2012-05-09 2020-03-30 Biogen Ma Inc Moduladores do transporte nuclear e usos dos mesmos
US20130303509A1 (en) 2012-05-11 2013-11-14 Abbvie Inc. Nampt inhibitors
MX2014013734A (es) 2012-05-11 2015-06-10 Abbvie Inc Inhibidores de nampt.
CA2873075A1 (en) 2012-05-11 2013-07-14 Abbvie Inc. Nampt inhibitors
CN104271572A (zh) 2012-05-11 2015-01-07 艾伯维公司 用作nampt抑制剂的噻唑羧酰胺衍生物
EA028136B1 (ru) 2012-06-19 2017-10-31 Дибиофарм Интернешнл Са Пролекарственные производные (е)-n-метил-n-((3-метилбензофуран-2-ил)метил)-3-(7-оксо-5,6,7,8-тетрагидро-1,8-нафтиридин-3-ил)акриламида
US9938258B2 (en) 2012-11-29 2018-04-10 Karyopharm Therapeutics Inc. Substituted 2,3-dihydrobenzofuranyl compounds and uses thereof
WO2014144772A1 (en) 2013-03-15 2014-09-18 Karyopharm Therapeutics Inc. Methods of promoting wound healing using crm1 inhibitors
CN105339358B (zh) 2013-06-21 2019-06-04 卡尔约药物治疗公司 核转运调节剂及其用途
AU2014285019C1 (en) 2013-07-03 2019-05-02 Karyopharm Therapeutics Inc. Substituted benzofuranyl and benzoxazolyl compounds and uses thereof
US9994558B2 (en) 2013-09-20 2018-06-12 Karyopharm Therapeutics Inc. Multicyclic compounds and methods of using same
US20160229835A1 (en) * 2013-10-09 2016-08-11 Eli Lilly And Company Novel pyridyloxyacetyl tetrahydroisoquinoline compounds useful as nampt inhibitors
US20170204092A1 (en) 2014-07-23 2017-07-20 Aurigene Discovery Technologies Limited 4,5-dihydroisoxazole derivatives as nampt inhibitors
MA40254B1 (fr) 2014-08-15 2022-09-30 Karyopharm Therapeutics Inc Polymorphes du selinexor
WO2016112075A1 (en) 2015-01-06 2016-07-14 Arena Pharmaceuticals, Inc. Methods of treating conditions related to the s1p1 receptor
CN104447486B (zh) * 2015-01-13 2016-06-01 佛山市赛维斯医药科技有限公司 二烯氟代金刚烷类化合物、其制备方法和用途
CN104447483B (zh) * 2015-01-13 2016-07-27 佛山市赛维斯医药科技有限公司 含苯胺和二烯金刚烷结构的化合物、其制备方法和用途
CN104447484B (zh) * 2015-01-13 2016-06-08 佛山市赛维斯医药科技有限公司 含烷氧苯基和二烯金刚烷结构的化合物、其制备方法和用途
SI3310760T1 (sl) 2015-06-22 2023-02-28 Arena Pharmaceuticals, Inc. Kristalinična L-argininska sol (R)-2-(7-(4-ciklopentil-3-(trifluorometil)benziloksi)-1,2,3,4- tetrahidrociklo-penta(b)indol-3-il)ocetne kisline za uporabo pri motnjah, povezanih z receptorjem S1P1
CN108137563A (zh) 2015-08-18 2018-06-08 卡尔约药物治疗公司 用于治疗癌症的(S,E)-3-(6-氨基吡啶-3-基)-N-((5-(4-(3-氟-3-甲基吡咯烷-l-羰基)苯基)-7-(4-氟苯基)苯并呋喃-2-基)甲基)丙烯酰胺
TW201720802A (zh) * 2015-09-15 2017-06-16 艾森伯利生物科學公司 B型肝炎核心蛋白質調節劑
WO2017117535A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Nuclear transport modulators and uses thereof
MA43529A (fr) 2015-12-31 2018-11-07 Karyopharm Therapeutics Inc Modulateurs de transport nucléaire et leurs utilisations
WO2017117447A1 (en) 2015-12-31 2017-07-06 Karyopharm Therapeutics Inc. Multicyclic compounds and uses thereof
BR122023021456A2 (pt) 2016-02-26 2024-02-20 Debiopharm International S.A. Uso de di-hidrogeno fosfato de {6- [(e)-3-{metil[(3-metil-1-benfofuran-2- iol)metil]amino)-3- oxopro-1-en-1-il]-2-oxo-3,4-di-hidro-1,8-naftiridin-1(2h)- il}metila para tratamento de osteomielite do pé diabético e composição farmacêutica
EP3279192A1 (en) * 2016-08-05 2018-02-07 Centre Hospitalier Universitaire Vaudois (CHUV) Piperidine derivatives for use in the treatment of pancreatic cancer
WO2018086703A1 (en) 2016-11-11 2018-05-17 Bayer Pharma Aktiengesellschaft Dihydropyridazinones substituted with phenylureas
WO2018098472A1 (en) 2016-11-28 2018-05-31 Karyopharm Therapeutics Inc. Crm1 inhibitors for treating epilepsy
CN107827897A (zh) * 2017-10-23 2018-03-23 青岛大学 一种手性七元螺环吲哚酮类化合物的合成方法
CA3089754A1 (en) 2018-01-31 2019-08-08 Bayer Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
CN108558840B (zh) * 2018-06-04 2020-11-06 上海交通大学 水溶性氮杂α-萘黄酮类化合物及其制备方法和医药用途
WO2021013693A1 (en) 2019-07-23 2021-01-28 Bayer Pharma Aktiengesellschaft Antibody drug conjugates (adcs) with nampt inhibitors
KR20220110744A (ko) 2019-11-06 2022-08-09 레미디 플랜, 인크. 암 줄기 세포를 표적화하는 암 치료
JP2024518089A (ja) 2021-05-13 2024-04-24 リメディー プラン,インコーポレーテッド Nampt阻害剤とその使用

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4283541A (en) 1980-05-27 1981-08-11 Usv Pharmaceutical Corporation Pyridylacyl-hydroxamates
NL8005133A (nl) 1980-09-12 1982-04-01 Duphar Int Res Fenylpiperazinederivaten met antiagressieve werking.
US5326772A (en) 1984-09-28 1994-07-05 Byk Gulden Lomberg Chemische Fabrik Gmbh Diaryl compounds for their use
US4778796A (en) 1985-07-19 1988-10-18 Dainippon Pharmaceutical Co., Ltd. ω-(3-pyridyl)alkenamide derivatives and anti-allergenic pharmaceutical compositions containing same
DE3641822A1 (de) 1986-12-06 1988-06-16 Goedecke Ag Verwendung von dihydrophenylaminosaeurederivaten und diese enthaltende arzneimittel zur immunmodulation und cytostase
JPS63179869A (ja) 1987-01-20 1988-07-23 Dainippon Pharmaceut Co Ltd ピペリジン誘導体
JP2832979B2 (ja) * 1988-02-15 1998-12-09 武田薬品工業株式会社 不飽和カルボン酸アミド誘導体
AU638205B2 (en) 1988-02-19 1993-06-24 Byk Gulden Lomberg Chemische Fabrik Gmbh Optically pure r-(-)-niguldipine and its derivatives for treating tumorous diseases
EP0343307A1 (en) * 1988-05-26 1989-11-29 Fabrica Espanola De Productos Quimicos Y Farmaceuticos, S.A. 4-Piperidinealkanamine derivatives
IE903196A1 (en) 1989-09-05 1991-03-13 Searle & Co Substituted n-benzylpiperidine amides
IE903957A1 (en) 1989-11-06 1991-05-08 Sanofi Sa Aromatic amine compounds, their method of preparation and¹pharmaceutical compositions in which they are present
CA2080127A1 (en) 1990-04-10 1991-10-11 Peter Zimmermann Pyridines as medicaments
JPH05506027A (ja) 1990-04-10 1993-09-02 ビイク グルデン ロンベルク ヒエーミツシエ フアブリーク ゲゼルシヤフト ミツト ベシユレンクテル ハフツング 新規ピリジンエステル
DE4020570A1 (de) 1990-06-28 1992-01-02 Hoechst Ag 2,4- und 2,5-substituierte pyridin-n-oxide, verfahren zu deren herstellung sowie deren verwendung
US5260323A (en) 1990-06-28 1993-11-09 Hoechst Aktiengesellschaft 2,4- and 2,5-substituted pyridine-N-oxides, processes for their preparation and their use
ES2069137T3 (es) 1990-07-30 1995-05-01 Takeda Chemical Industries Ltd Derivados de imidazopiridina y su uso.
US5229400A (en) 1990-10-05 1993-07-20 Ajinomoto Co., Inc. Piperidine compounds and their use as antiarrhythmic agents
FR2676053B1 (fr) 1991-05-03 1993-08-27 Sanofi Elf Nouveaux composes dialkylenepiperidino et leurs enantiomeres, procede pour leur preparation et compositions pharmaceutiques les contenant.
ATE136296T1 (de) 1991-05-10 1996-04-15 Takeda Chemical Industries Ltd Pyridinderivate, deren herstellung und anwendung
US5208247A (en) 1991-08-01 1993-05-04 American Cyanamid Company Pyridinium compounds which are useful as antagonists of platelet activating factor
CA2085954A1 (en) 1991-12-24 1993-06-25 Klaus Weidmann Substituted pyridine n-oxides, processes for their preparation, and their use
CA2126976A1 (en) 1991-12-31 1993-07-08 Hisashi Takasugi Oxadiazole derivatives having acetylcholinesterase-inhibitory and muscarinic agonist activity
FR2686084B1 (fr) 1992-01-10 1995-12-22 Bioprojet Soc Civ Nouveaux derives de l'imidazole, leur preparation et leurs applications therapeutiques.
GB9200535D0 (en) 1992-01-10 1992-02-26 Fujisawa Pharmaceutical Co New compound
US5612336A (en) 1992-07-13 1997-03-18 Merck, Sharp & Dohme Ltd. Heterocyclic amide derivatives as tachykinin antagonists
IL111235A (en) 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
CA2174105C (en) 1993-10-15 2002-02-12 W. Robert Bishop Tricyclic carbamate compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
HUT76057A (en) 1993-10-15 1997-06-30 Schering Corp Tricyclic sulfonamide compounds, pharmaceutical compositions containing them, which are useful for inhibition of g-protein function and for treatment of proliferative diseases and process for producing them
WO1995024894A2 (en) 1994-03-14 1995-09-21 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Use of lipoxygenase inhibitors as anti-cancer therapeutic and intervention agents
IL117798A (en) 1995-04-07 2001-11-25 Schering Plough Corp Tricyclic compounds useful for inhibiting the function of protein - G and for the treatment of malignant diseases, and pharmaceutical preparations containing them
US5712280A (en) 1995-04-07 1998-01-27 Schering Corporation Tricyclic compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
FR2738245B1 (fr) 1995-08-28 1997-11-21 Sanofi Sa Nouveaux derives de piperidine, procede pour leur obtention et compositions pharmaceutiques les contenant
US6451816B1 (en) * 1997-06-20 2002-09-17 Klinge Pharma Gmbh Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides in the treatment of tumors or for immunosuppression
DE19624659A1 (de) * 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalken- und Pyridylalkinsäureamide
DE19624668A1 (de) 1996-06-20 1998-02-19 Klinge Co Chem Pharm Fab Verwendung von Pyridylalkan-, Pyridylalken- bzw. Pyridylalkinsäureamiden
DE19624704A1 (de) 1996-06-20 1998-01-08 Klinge Co Chem Pharm Fab Neue Pyridylalkansäureamide

Also Published As

Publication number Publication date
CZ409398A3 (cs) 1999-05-12
AU3262597A (en) 1998-01-07
BR9709823B1 (pt) 2013-09-17
CA2257448A1 (en) 1997-12-24
CN1546472A (zh) 2004-11-17
AU736206B2 (en) 2001-07-26
HU225715B1 (en) 2007-07-30
JP2000516913A (ja) 2000-12-19
IL127352A (en) 2003-10-31
CA2257448C (en) 2008-08-19
JP4225572B2 (ja) 2009-02-18
CZ291791B6 (cs) 2003-05-14
DK0923570T3 (da) 2003-01-20
CN1228777A (zh) 1999-09-15
DE69715888T2 (de) 2003-07-31
IL127352A0 (en) 1999-10-28
EP0923570B1 (en) 2002-09-25
ZA975437B (en) 1998-02-10
US20070219197A1 (en) 2007-09-20
DE19624659A1 (de) 1998-01-08
US7241745B2 (en) 2007-07-10
US20030162972A1 (en) 2003-08-28
US20070142377A1 (en) 2007-06-21
ES2179351T3 (es) 2003-01-16
BR9709823A (pt) 1999-08-10
DE69715888D1 (de) 2002-10-31
CN1152032C (zh) 2004-06-02
ATE224888T1 (de) 2002-10-15
RU2200734C2 (ru) 2003-03-20
HUP9903766A3 (en) 2000-12-28
PT923570E (pt) 2002-12-31
TR199802651T2 (xx) 1999-04-21
HUP9903766A2 (en) 2000-09-28
EP0923570A1 (en) 1999-06-23
WO1997048696A1 (en) 1997-12-24

Similar Documents

Publication Publication Date Title
HK1021974A1 (en) Pyridyl alkene-and pyridyl alkine-acid amides as cytostatics and immunosuppressives
AU3342097A (en) New pyridyl alkane acid amides as cytostatics and immunosuppressives
ZA975443B (en) Use of pyridyl alkane, pyridyl alkene and/or pyridyl alkine acid amides.
UA74346C2 (uk) Похідні амінодикарбонових кислот, їх застосування та лікарський засіб
MX9604378A (es) Amidas de acido quinolin-2-carboxilico sustituidas, su preparacion y su empleo como medicamentos, asi como productos intermedios.
MX9503529A (es) Derivados de glicinamida, procedimiento para su preparacion y medicamentos que los contienen.
GB9902412D0 (en) Process
ZA9811235B (en) New piperazinyl-substituted pyridylalkane alkene and alkine carboxamides
GB9813540D0 (en) Chemical compounds
GR3033034T3 (en) Novel pyrazine carboxamide derivatives, their production and their use in medicaments
ZA9811240B (en) New aryl-substituted pyridylalkane alkene and alkine carboxamides
UA49884C2 (uk) ПОХІДНІ <font face="Symbol">a</font>-ГІДРОКСИКАРБОНОВОЇ КИСЛОТИ ТА ЛІКАРСЬКИЙ ЗАСІБ НА ЇХ ОСНОВІ
ATE188873T1 (de) Tris-platin-komplexe
ATE192923T1 (de) Verwendung von boswelliasäure zur behandlung von hirntumoren
HU9201799D0 (en) New 2-amino-5-ciano-1,4-dihydropiridine-derivatives, process for their use and their use as medicaments
AU6011001A (en) Novel lhrh-antagonists, production and use thereof as medicament
IL134192A0 (en) Thiazolobenzoheterocycles, their preparation and medicines containing same
ZA986336B (en) Medicaments comprising polyhydroxybutylpyrazines novel polyhydroxybutylpyrazines and their preparation
MD457G2 (ro) Derivaţi noi de naftiridină, procedeu de preparare a lor, compoziţii farmaceutice care le conţin, utilizarea lor ca medicamente de antireproducere
ZA858316B (en) Pyrazine diazohydroxide compounds and methods for production and use
AU2003298203A1 (en) Medicaments containing substituted 2,5-diaminomethyl-1h-pyrroles
ES2200706A1 (es) Derivados de 4-4'-bipiridil-2-2'-bisoxazoles y 4-4'-bipiridil-2-2'-bistiazoles como agentes antineoplasicos.
MX9700388A (es) Ciclopentanopiridil-oxazolidinonas que contienen heteroatomos.
MX9700421A (es) Tienil- y furanil- oxazolidinonas piridocondensadas.

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20120620